CytRx Announces Phase I HIV Vaccine Clinical Trial Enrollment Completion
CytRx, Advanced BioScience Laboratories and the University of Massachusetts Medical School has completed enrollment of healthy volunteers in a three-arm Phase I clinical trial for a novel HIV DNA vaccine.
The primary objective of the Phase I clinical trial is to determine the safety and tolerability of different dosages and routes of administration of the DNA vaccine, and a fixed dosage and route of administration of an HIV protein boost.
The vaccine strategy is to assess in human volunteers whether a DNA vaccine with a protein boost can stimulate both antibody and T-cell immune responses to the virus as previously demonstrated in animal models. To date, the vaccine has been well-tolerated in humans.